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INTRODUCTION
Cancer represents a leading cause of death whose 
incidence is steadily increasing worldwide due to the 
population aging and to lifestyle behaviors, as smoking, 
overweight and physical inactivity. Gender disparity 
in the incidence, aggressiveness and disease prognosis 
have been observed for a variety of cancers. Despite 
this, clinical trials and research in animal models have 
been gender unbalanced. Gender-specific oncology 
needs to reconstruct a balance in order to understand 
the molecular basis underlying the gender differences 
in the outcome and response to therapy of cancer. The 
comprehension of the biological mechanisms respon-
sible for sex-biased differences may yield improved can-
cer management and the development of personalized 
therapeutic strategies. 
The words sex and gender are quite distinct. In fact, 
sex is referred to the biologic characters that distinguish 
males and females as expressed by the analysis of the 
person’s gonadal, morphologic (internal and external), 
chromosomal and hormonal features. By contrast, gen-
der refers to behaviors, roles, expectations and activities 
in society. In other words, gender refers to socio-cultur-
al or learned significance of sex. The current distinction 
between sex and gender difference has been criticized 
as misleading and counterproductive, especially in the 
field of medicine. In this review we decided to use the 
terms gender and sex interchangeably.
GENDER DISPARITIES OF CANCER: 
EPIDEMIOLOGY AND MOLECULAR BASIS 
Growing evidences are showing gender-associated 
functions playing a role in cancer incidence, progres-
sion and response to therapy. At present cancer repre-
sents the leading cause of death, approximately 13% of 
all deaths, as reported by The Global Health Observa-
tory of the World Health Organization (WHO). Cancer 
incidence and mortality for 2012 were estimated by sex 
and age groups for each of the 39 European countries, 
defined by United Nations (UN) plus Cyprus. 
According to the European Network of Cancer Reg-
istries (ENCR) member registries, the WHO mortality 
database and UN population data, the amounts esti-
mated in 2012 in Europe by type of cancer were over 
3.4 million of new cases (excluding non-melanoma skin 
cancers), 53% (1.8 million) occurring in men and 47% 
(1.6 million) in women. The most common cancer sites 
were breast cancer (464 000 cases, 13.5% of all cancer 
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Abstract 
Cancer represents a leading cause of death whose incidence is steadily increasing world-
wide due to the population aging. The Global Health Observatory of the World Health 
Organization reported that approximately 13% of all deaths are caused by cancer. In the 
2012 the estimated total number of cancer deaths was 1.75 million, 56% in men and 
44% in women. Gender is recognized to play a role in cancer incidence, progression and 
response to therapy. Besides anatomical and hormonal disparities, genetic differences 
should be considered when assessing the effects of gender on cancer. Accumulating evi-
dence also support the existence of sex-driven differences in immune responses. 
Until today clinical trials and research in animal models have been gender unbalanced. 
In consideration of the differences between sexes observed in cancer, sex should repre-
sent an important stratification factor to be included in all randomized clinical trials for 
a better understanding of biological differences between men and women, which may 
yield improved targeted therapies.
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cases), followed by colorectal cancer (447 000, 13.0%), 
prostate cancer (417 000, 12.1%) and lung cancer (410 
000, 11.9%), representing half (50.5%) of the estimated 
overall burden. In the same year the estimated total 
number of cancer deaths was 1.75 million, 56% in men 
and 44% in women.
Based on these numbers and considering the differ-
ences observed in tumor location, incidence, aggressive-
ness and response to therapies, it appears of outmost 
importance to introduce a gender-derived approach in 
cancer research. Moreover the comprehension of bio-
logical and socio-cultural specificities associates either 
with sex or gender would provide better results in pre-
vention and therapeutic strategies. Nonetheless, really 
few preclinical studies use animals of both sexes to in-
vestigate the molecular mechanisms underlying cancer 
development and results derived from clinical trials are 
not evaluated taking in mind sex and gender.
Besides anatomical and hormonal disparities, genetic 
differences should be considered when assessing the ef-
fects of gender on diseases. Different studies showed 
the female advantage in several different cancer types. 
Based on EUROCARE-4 cancer cases, in Europe a sig-
nificant advantage of women was reported for 16 out 
of 26 types of cancer [1]. Representative examples of 
gender disparities have been associated with colorec-
tal cancer, urothelial and kidney cancer [2] as well as 
melanoma [3]. 
Colorectal cancer, the third most common cancer in 
the world, is characterized by sex- and gender-specific 
differences, as women appear more prone than men to 
right-sided colon cancer, a more aggressive form of this 
neoplasia. Depending on tumor site, colorectal cancer 
is associated with different molecular and pathologi-
cal characteristics: microsatellite instability (MSI) and 
BRAF mutation often observed in right-sided colon 
cancer and chromosomal instability more often in left-
sided (60%-70% of cases) [4]. Hormonal factors might 
explain a large percentage of right-sided colorectal can-
cer in females as estrogen appears a protective factor 
against MSI as suggested by the increased risk of MSI-
high colon cancer in older women. Accordingly the 
Women’s Health Initiative Clinical Trial reported that 
postmenopausal women undergoing hormone replace-
ment therapy showed a 40% reduction in colorectal 
cancer risk [5]. In addition, besides sexual differences 
in anatomy and physiology of the colon (longer trans-
verse colon in women), socio-cultural differences, as 
dietary factors, should be considered. 
A gender discrepancy exists in the incidence of blad-
der cancer, renal cell carcinoma (RCC) and urothelial 
carcinoma (UTUC), although few data are available for 
the latter. Evidences suggest that men present these 
cancers more than women. Conversely, female gen-
der seems to represent a negative prognostic factor of 
bladder cancer survival, but it seems to be protective 
in patients with UTUC or RCC [2]. Smoking habits, 
occupational risk factors, tumour biology and sex ste-
roid hormones and their receptors could all have a role 
in causing the observed gender disparities in patients 
with urological cancers. Interestingly, a meta-analysis of 
gene expression in clear cell RCC showed that, among 
the total number of genes analyzed, 89% were differen-
tially expressed between genders [6]. More accurate di-
agnosis and stratification on higher numbers of patients 
should be evaluated to actually discriminate the actual 
sex associated disparities.
Although female sex is associated with a survival ad-
vantage in several cancer types, studies in both Europe 
and United States showed that this advantage was con-
siderably higher in melanoma than in virtually any other 
type of cancer. 
Since the late 1960s, Clark observed that cutane-
ous melanoma was more aggressive in men [7]. More 
recently, according to EUROCARE4 data, melanoma 
was reported to display the more significant female 
advantage in survival of cancer patients [1]. Based on 
1.6 million population, women resulted to have an esti-
mated overall 2% lower relative risk of dying from mela-
noma in comparison to men and melanoma survival was 
50% higher in women compared with men. Seemingly 
in 2014, in the United States women only accounted 
for 42% of the new cases and only 33% of the deaths. 
Further insights were provided on the prognostic effect 
of sex in a population group of approximately 4000 skin 
melanomas in central Italy. Data confirmed that women 
had a 34% lower risk compared with men of dying from 
skin melanoma [8]. Nonetheless the protective factor 
is still unknown. Although the source of gender dispar-
ity in melanoma remains unclear, two main hypotheses 
for female advantage can be offered: 1) differences in 
behavior and 2) unknown biologic sex differences [9].
The most evident behavioral differences are repre-
sented by a general earlier detection of lesions due to 
female more observed health care. Another variation 
possibly associated with gender is the site of primary 
melanoma, more often on the extremities for women 
and on the trunk for men. Melanomas localized on the 
legs could be more easily visible respect to the back, but 
more exposed to UV [10]. 
Looking for the underlying molecular mechanisms, 
tumor itself does not really appear to diverge across 
gender as confirmed by several studies showing no dif-
ferences in mutation rates of some important genes 
in melanoma, most notably in the BRAF gene. None-
theless several host factors, which differ across gender 
have been linked to melanoma progression and survival 
and might therefore offer an explanation for the female 
melanoma advantage. These include hormone levels 
(estrogens and androgens, estrogen receptor β), the im-
mune system, autophagy, matrix metalloproteinase-2, 
skin physiology, vitamin D, obesity and reactive oxygen 
species. In fact all these molecules and biological pro-
cesses have been hypothesized to display sex disparities 
(Figure 1). As an example, it is known that males ex-
press lower amounts of anti-oxidant enzymes, resulting 
in more oxidative stress than females [11]. On the con-
trary, melanoma incidence and progression do not seem 
actually influenced by estrogens as the female survival 
advantage seems to persist in postmenopausal age [12].
Melanomas in women have a lower propensity to 
metastasize, resulting in a better survival when com-
pared with men, thus suggesting differences in tumor-
host interaction across gender. In fact women display a 
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significantly lower risk of both lymph node and distant 
metastases when compared with men, even after adjust-
ment for relevant prognostic factors. Indeed melanoma 
is a highly immunogenic tumor, likely inducing immu-
nosuppression, and gender is known to influence the 
immune system [13].
Finally several studies suggest a role for X linked genes 
in sex-based cancer outcome differences, including in 
melanoma. A key factor in X-chromosome inactivation 
is DNA methylation thus indicating that epigenetics 
contribute to sex-specific metabolic phenotypes [14]. 
Although in women X chromosome undergoes inactiva-
tion of one copy in each cell, due to escape or variation 
of inactivation X chromosome, heterogeneity does ex-
ist and female tissues are mosaics. Conversely, men are 
identically monosomic for the maternal X chromosome. 
Finally, particularly intriguing appear sex differences 
associated with microRNAs, whose deregulation has 
been significantly associated with cancer progression. 
MicroRNAs are small non-coding RNAs involved in the 
post-transcriptional regulation of up to 70% of protein-
coding genes. In addition, differential microRNA ex-
pression has been reported in males and females and 
their possible contribution associated to sex disease 
outcome. Differences in the expression of microRNAs 
can depend on a differential regulation by sex chromo-
some genes, as the X chromosome shows a high density 
of microRNAs, 2-fold higher than autosomes. Accord-
ing to miRBase microRNA archive (www.miRBase.org 
2013), the X chromosome encodes 113 microRNAs 
and the Y chromosome only 2. Hence sex differences in 
microRNA expression seem a result of both hormonal 
and genetic differences [15]. Possible examples are 
miR-29a and -29b induced by estrogens in women and 
protecting against liver fibrosis by reducing collagen 
deposition associated with cancer dissemination [16]. 
Also, in view of their localization on the X chromosome, 
miR-221&222 as well as the miR-506-514 cluster could 
be related with sex differences. Oncogenic roles have 
been demonstrated for both these microRNA groups 
in melanoma progression and melanocyte transforma-
tion [17]. 
SEX DIFFERENCES IN IMMUNO-ONCOLOGY 
AND ANTICANCER IMMUNOTHERAPY
Accumulating evidence support the existence of sex-
driven differences in immune responses as potential 
factors contributing to diverse disease outcome as well 
as response to therapies in males and females [18]. The 
sex-bias in the immune response is due to diverse de-
terminants: the direct effects of X- or Y-chromosome 
linked genes, the indirect effects of sex hormones and 
the environmental risk factors that act in a sex-specific 
manner [19]. X-linked genes as well as unique genes 
on the Y chromosome play a crucial role in the diver-
gence between male and female immune responses. 
On this basis, the X chromosome may be considered 
partially responsible for the immunological advantage 
of females that are characterized by increased immune 
reactivity. In fact, numerous genes, directly and indi-
rectly involved in immunity, are encoded by the X chro-
mosome, conferring a sex-based advantage not only due 
to the prevention of the deleterious effects of heterozy-
gous-linked gene-mutations but also to the benefit of a 
greater diversity appropriate to face new immune chal-
lenges, such as infections or vaccines [20]. Accordingly, 
mutations in some X-linked immune genes, such as the 
IL-2 receptor gamma chain or FOXP3, lead to severe 
dysregulated immune phenotypes in males, while fe-
males result relatively unaffected [19]. Moreover, be-
ing miRNAs critical regulators of the development of 
immune cells and of the maintenance of immune sys-
tem homeostasis, their unbalanced massive presence 
on the X chromosome implies a potential dysregulation 
associated to female-specific immune diseases [21]. 
The second main cause of sex-bias differences in im-
munity is the influence of sex hormones on immune 
cells. In fact, through specific receptors, sex hormones 
control the development and function of multiple im-
mune cell populations, shaping innate and adoptive 
immune responses [22]. Estrogens regulate inflamma-
tory pathways of macrophages in a dosage-dependent 
manner and suppress neutrophils; they also have a re-
markable impact on the differentiation and activation 
of dendritic cells (DCs), including important DC sub-
sets target for immunotherapies, such as plasmacytoid 
DCs (pDCs) [23]. In this regard, it has been recently 
reported that sex differences of IRF5 in pDCs drive 
higher IFN-α production in women than in men [24]. 
Estrogens increase NK cytotoxicity and the production 
of pro-inflammatory cytokines such as IL-1, IL-6 and 
TNF-α whereas androgen exert opposite effects on NK 
cells and stimulate the production of IL-10 [25]. Im-
portantly, women have on average higher frequency of 
circulating CD4+ T-cells then men [26]. Estrogens influ-
ence the maturation of T lymphocytes and regulate T-
helper (Th)1 and Th2 responses in a dosage-dependent 
manner, since low doses promote Th1-mediated immu-
nity, whereas higher doses skew the immune response 
towards Th2. In addition, they regulate Th17 lineage 
polarization and drive the expansion and the functional 
capacity of Tregs. Indeed, these cells are dramatically 
sensitive to changes in the levels of sex hormones dur-
ing the ovarian cycle, since their frequency increase in 
the follicular phase upon estrogen level enhancement 
and decrease during the luteal phase when estrogens go 
down and progesterone is high. Thus, sex hormones ex-
ert an additional control on effector T cells throughout 
Treg, determining the outcome of adaptive immunity. 
B cell development and humoral immune response are 
also shaped by estrogens that drive the enhancement of 
B cell subsets and control the levels of immunoglobulins 
(Ig), in particular IgG and IgM. In fact, one of the most 
evident sex-specific immune differences is the ability 
of females to produce more elevated circulating levels 
of antibodies than males, attesting their capability to 
produce much stronger humoral immune responses 
[27]. Regarding the control of sex hormones on im-
mune cells, recently it has been described the capabil-
ity of these factors to alter the epigenetic regulation of 
gene expression by affecting epigenetic modifications, 
in particular DNA methylation and chromatin remodel-
ing, thus adding an important level of influence on the 
differentiation and the activation of immune cell popu-
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lations. Thus, a sex-specific epigenetic mechanism for 
immune modulation is also envisaged [23]. The third 
factor concurring to determine sex-specific immunity is 
a complex network of environmental components  (see 
Figure 2 for a schematic description of sex differences 
in immune phenotype and in anticancer response to im-
munotherapy). Although the exposure to antigens, such 
as pathogens, chemicals and xenobiotics, and food in-
take and variety are important in orchestrating immune 
responses, the microbiome-related factors seem to be 
the most important source vigorously influencing the 
expression of sex-specific immune phenotypes. Recent-
ly, it has become evident a tight dialogue between the 
commensal gut microbiome and host hormones. In this 
bidirectional interaction, host hormones control micro-
biome composition and, in turn, the microbiome influ-
ences sex hormone levels of the host shaping hormone-
dependent immune responses [28]. In addition, sex 
hormones control gut local immunity shaping a crucial 
crosstalk between immune and epithelial cells. In fact, 
estrogens activate in situ a wide range of pro-inflam-
matory signals, including differentiation of IL-12-pro-
ducing DC, polarization of Th1/Th17, B cell activation 
and activation of Toll-like receptors pathways. These 
events concur to generate pro-inflammatory environ-
ment which determine the dysfunction of gut permea-
bility allowing the translocation of gut bacteria into the 
lamina propria, that in turn engages the amplification of 
pro-inflammatory responses. Altogether, sex-associated 
factors determine specific immune phenotypes display-
ing deep differences in male and female with the con-
sequence that women generally exhibit more robust im-
munity against infections, higher allograft rejection and 
increased rate of autoimmunity than men [29]. Surpris-
ingly, in this scenario the sex-driven immune response 
to anticancer treatments targeting the immune system 
remains the less investigated issue in the field.
The antitumor immunity is fundamental in shaping 
the outcome of several anticancer therapies, includ-
ing conventional chemotherapy and radiation therapy, 
because behind their direct main action driven by tu-
moricidal properties toward fast-dividing cancer cells, 
these treatments exert profound effects on immune 
cells within the tumor microenvironment (TME) main-
ly by recruiting tumor-infiltrating leukocytes to this site 
upon rebound effects, that in turn regulate the over-
all immune response to therapy. However, the antitu-
mor response driven by effector CD8+ T cells is often 
dampen by the immunosuppressive microenvironment 
in place mediated by a multitude of immune cells 
and counterregulatory mechanisms [30]. By targeting 
these components, cancer immunotherapy has shown 
to elicit remarkable long-lasting responses in patients 
with a variety of advanced cancer as compared with 
conventional chemotherapy. In this landscape, the sex 
disparity in eliciting antitumor response with a specific 
immune phenotype may have a dramatic impact on the 
efficacy of cancer immunotherapies. This assumption is 
fundamental in the evaluation and implementation of 
the recently developed immune checkpoint inhibitors 
(ICI), that represent a pillar of cancer therapy, since 
they have revolutionized treatment and outcome of 
severe and often fatal cancers, with long-term tumor 
control and extended patient survival [31]. Nowadays, 
three ICI (ipilimumab, nivolumab, pembolizumab) and 
one (nivolumab) are treatments of choice for melanoma 
Figure 1
Biological processes possibly contributing to sex disparities in melanoma. The schematic picture shows the main mechanisms associ-
ated with women better outcomes. 
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and non-small-cell lung carcinoma, respectively. Never-
theless, since ICI affect T-cell function, treatment-as-
sociated side effects have challenged oncologists with 
a novel spectrum of toxicity, causing reduced dosage, 
delayed drug administration and therapy discontinua-
tion.  In this regard, a fundamental aspect still totally 
unexplored is the sex disparity in immune and toxic 
responses and their relationship. Importantly, among 
toxic effects, one of the most severe is colitis, due to the 
change in microbiome, causing dysfunction of intesti-
nal barrier [32]. These evidences necessarily recall the 
importance to take into consideration the sex-driven 
differences in microbiome composition. 
In spite of the growing body of indications suggesting 
the leading role of sex-bias in the response to cancer 
immunotherapy, the absence of knowledge in this field 
is largely due to two major causes, specifically animal 
researches performed with only one sex and under-en-
rollment of women in clinical trials [33]. Nevertheless, 
some studies suggest important mechanisms by which 
sex is likely to affect the response to immunological-
based anticancer treatments, such as anti-PD1-based 
immunotherapy. PD-1 receptor is expressed by ac-
tive T cells and when it is bound to PDL-1, aberrantly 
expressed by cancer cells, it suppresses the immune 
response of T cells. By blocking PD-1 receptors with 
anti-PD-1 mAbs, T cells are free to respond to cancer 
antigens and attack tumor cells [34]. Importantly, it has 
been shown that estrogens enhance Treg suppressive 
activity, throughout PD-1-dependent and PD-1- in-
dependent pathways leading to significant differences 
in tumor immunity and immunotherapy responses in 
males and females [35]. Accordingly, B16 melanoma-
bearing female mice have been found to benefit more 
than the male counterpart from anti-PD-L1 therapy, 
partially due to greater PD-L1 blockade-mediated re-
duction of Treg function in females [36].
In the framework of immunotherapy another critical 
issue is the definition of tumor specific antigens toward 
which the immune response needs to be redirected. 
The ideal condition is to have antigens expressed exclu-
sively in cancer cells rather than normal tissues. In this 
view, cancer-testis antigens (CTA) represent promising 
candidates for immunotherapy since they are never ex-
pressed in any normal tissue besides testis but aberrant-
ly present in many types of human cancer. Hence, the 
identification of novel CTA is considered a prerequisite 
for the development of new cancer vaccine strategies 
[37]. Importantly, some CTA expressed in lung cancer, 
such as MAGE3 and NY-SAR-35, were found to be sig-
nificantly associated with male sex, whereas, the expres-
sion of Ropporin-1, a potential CTA target for multiple 
myeloma immunotherapy, seems remarkably higher in 
females [38]. Hence, the differential expression of CTA 
in males and females needs to be taken carefully into 
account in order to develop effective immunotherapeu-
tic strategies. 
Overall, given the magnitude of sex components driv-
ing immunity, the disparity between males and females 
in eliciting both innate and adoptive immune responses 
is crucial for defining the response to anticancer treat-
ments whose efficacy relies on the competence of the 
immune system. Hence, taking into account the sex 
issue in the design of anticancer immunotherapeutic 
strategies, and more in general of all therapies that tar-
get the immune system even only partially, is mandatory 
and represents a challenge as well as an opportunity for 
optimizing cancer treatments, including the manage-
ment of therapy-related toxicity. 
GENDER DISPARITIES IN EFFICACY  
AND TOXICITY OF ANTICANCER THERAPY 
Although gender disparity in the incidence of cancer, 
the aggressiveness and disease prognosis have been ob-
served for a variety of cancers, relatively little is known 
Figure 2
Influence of sex immune phenotype on anticancer response to 
immunotherapy. Specific determinants such as X-chromosome 
linked genes, sex hormones and environmental risk factors act 
in a sex-driven manner. The integration of the out coming sig-
nals determines the sex-biased immune-phenotypes that in 
combination with other elements, for instance the differential 
expression of CTA, shape diverse anticancer responses in males 
and females, affecting immunotherapy efficacy.
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and assessed about the gender differences in anticancer 
therapy and their impact in the clinical management of 
the disease. The low representation of women in clinical 
trials certainly represents a crucial factor that has lim-
ited, to date, the collection of data. In the last 30 years, 
too many epidemiological and clinical studies reported 
results in only one sex. This means that results obtained 
only in men, in terms of efficacy and toxicity, were 
transferred to the entire population, including women 
[39]. This aspect is very important for the implications 
either in drug-related toxicity or efficacy. 
Knowledge of the potential benefits and risks associ-
ated with the use of anticancer therapies is fundamen-
tal for making treatment-related recommendations and 
decisions. Emerging data from the literature about gen-
der differences are partial, fragmentary and sometimes 
contradictory. Due to the retrospective nature of these 
studies, there are numerous confounding factors (age, 
stage of disease, co-morbidity etc.) that may have im-
pacted results.
In general, it has been observed that some chemo-
therapy protocols lead to a better response rate in wom-
en without increasing toxicity (e.g. cisplatin and irino-
tecan), while others only increase toxicity, but do not 
improve response rates in women (e.g. 5-fluorouracil). 
Side effects appear to be highly dependent on different 
tissue properties, as women have a higher incidence of 
oral mucositis, but lower rates of gut toxicity than men. 
Nausea and vomiting is a greater problem in females 
during therapy due to the lower activity of anti-emetic 
drugs [40]. 
While the molecular mechanisms underlying these 
differences are not yet or only partially known, the in-
creased toxicity often correlates with different pharma-
cokinetics. 
Gender differences in drug pharmacokinetics and 
pharmacodynamics have been recognized to play a key 
role in drug efficacy and safety profile [41]. Although 
gender-related pharmacodynamics data are limited, 
evidence suggests that women i) are more prone to the 
development of side effects than men and ii) present 
different pharmacological response to drug treatment 
that could translate into a different clinical outcome. 
Physiological differences between male and female 
exist in tissue specific metabolism. The liver is one 
example. Sexual differences have been described for 
hepatic transport, as well as for enzymatic activities, 
drug detoxification and lipid metabolism [42]. For ex-
ample: i) many detoxifying enzymes belonging to the 
cytochrome P450 (CYP) superfamily are expressed in 
the liver in a sex-dependent pattern; and ii) CYP3A4 
and CYP2B6, responsible for the metabolism of more 
than 50% of therapeutic drugs, exhibit higher activ-
ity in women than in men [43, 44]. According to this, 
women generally predominate among patients with 
drug-induced liver injury [45] and also they appear to 
be more susceptible to antineoplastic drug adverse re-
actions [46].
Sex differences in drug metabolism and elimination 
are also strictly related to steroid hormone levels. In 
fact, to further complicate this matter, drug metabo-
lism in women is affected by sex-specific factors such as 
menopause, pregnancy and menstruation. Thus, careful 
attention should be paid to the side effects and toxic-
ity arising from sex differences in drug metabolism in 
different clinical situations. Although there are specific 
ethical considerations regarding the inclusion of wom-
en in drug trials and their inclusion could increase the 
costs, in terms of both money and work, the relation-
ship between the side-effects and toxicity that may be 
influenced by hormones during drug metabolism and 
drug treatment needs to be deeply investigated. How-
ever, given the complexity of gender pharmacology as 
well as the limited availability of adequate animal mod-
els and human studies, specific gender disparities are 
quite difficult to be evidenced.
The following are some examples of gender dispari-
ties in toxicity and effectiveness of certain drugs used in 
the treatment of the most common cancers.
Despite the introduction of innovative drugs and bio-
logical agents in cancer therapy, anthracyclines remain 
among the most potent anticancer drug employed in 
numerous chemotherapy protocols of both hemato-
logic and solid tumors. However, their use is hindered 
by the risk of severe cardiotoxicity. According to this, a 
very recent study reports that clinical use of anthracy-
clines may lead to a progressive cardiomyopathy that 
may evolve to congestive heart failure [47]. As far as 
the gender difference was concerned, most of studies 
suggested that females develop less severe doxorubicin-
induced cardiomyopathy and nephropathy than males 
[48]. A recent experimental paper, performed by Gon-
zales et al. in tumor-bearing spontaneously hypertensive 
rats, shows that males were more sensitive to doxoru-
bicin-induced cardiotoxicity. In particular, the authors 
showed that females exhibited more down-regulation 
of apoptotic and oxidative stress genes than males af-
ter doxorubicin administration. In addition, they also 
found that reproductive hormone levels were inversely 
correlated with cardiac health [47]. This is in accord 
with the fact that the myocardium is functionally re-
sponsive to circulating reproductive hormones, as car-
diac tissues express both androgen and estrogen recep-
tors [49]. Especially, estrogens have been suggested to 
function as a cardio-protectant through the prevention 
of cardiomyocyte apoptosis and alleviation of left ven-
tricular hypertrophy thus providing protection against 
the development of cardiac fibrosis in women [50]. A 
further important issue emerging from this paper is 
the observation of a gender disparity in doxorubicin-
induced anticancer activity. In particular, in male ani-
mals a significant greater tumor reduction was found in 
comparison with female animals. 
In contrast with that reported by Gonzales and co-
workers, Moulin et al. did not observed either oxidative 
stress or cell death as determinant of sexual dimor-
phism in doxorubicin-cardiotoxicity. In this paper, per-
formed in adult rats, doxorubicin-induced cardiotoxici-
ty, observed only in males, was accompanied by an early 
mitochondrial dysfunction and altered energy signaling 
pathways together with cardiolipin homeostasis. These 
data strongly emphasized the role of mitochondrial dys-
function in doxorubicin cardiotoxicity and further pos-
sible role in the observed sex-differences [48]. 
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Amrubicin, an anthracycline derivative, is a com-
pletely synthetic agent, which is distinguishable from 
other anthracyclines discovered through natural prod-
ucts. It has been designed to have an antitumor activity 
that is from 5 to 200 times greater than that of its par-
ent compound. The use of Amrubicin in phase II trials 
monotherapy for lung cancer had shown a dose-limiting 
toxicity due to neutropenia, and severe hematological 
toxicities [51]. A retrospective analysis to identify pre-
treatment factors associated with severe hematological 
toxicity point to, among others, the female gender as 
significantly correlated with severe toxicity of clini-
cal relevance [52]. Bevacizumab, a monoclonal anti-
body targeting the vascular endothelial growth factor 
(VEGF), was approved by the U.S. Food and Drug Ad-
ministration (FDA) for use in combination with pacli-
taxel and carboplatin for patients with advanced stage 
of non-squamous lung cancer [53]. In fact, with the 
recognition of the importance of angiogenesis in can-
cer growth and metastasis [54], various therapies have 
been developed to block this pathway, including anti-
bodies against VEGF. Brahmer and co-worker reported 
that, in general, subjects treated with bevacizumab ex-
perienced antiangiogenesis therapy toxicities such as 
hypertension and hemoptysis. Comparing males and 
females, they found that females treated with bevaci-
zumab had a higher rate of grade ≥ 3 hypertension com-
pared to males, while hemoptysis, other bleeding events 
and proteinuria occurred similarly between males and 
females. Importantly, whereas both progression free 
survival and response rate were improved with the addi-
tion of bevacizumab either in males or females, bevaci-
zumab was an active drug only in women in which sig-
nificantly increased the overall survival [55]. This is in 
accord with the observation that antibodies often have 
a longer half-life in women, which is associated with an 
improved response to therapy [40]. By contrast, other 
trials regarding bevacizumab in advanced colon cancer 
demonstrated a benefit both in males and females [56].
A better response to melanoma chemotherapy in 
women treated with dacarbazine in comparison with 
men was also reported [57] and a specific meta-analysis 
reports a better response in women than in men when 
adding tamoxifen to dacarbazine treatment [58]. By 
contrast, there were no differences in the female sur-
vival advantage between patients receiving interferon as 
well as BRAF V600E inhibitor vemurafenib [59]. 
Even in children and adolescents gender differences 
in anticancer drug efficacy and toxicity have been re-
ported [60]. In a study on 352 children treated for ana-
plastic large cell lymphoma, Wrobel et al. observed sig-
nificantly higher rates of toxicity in females, including 
grade 4 haematologic toxicity and grade 3-4 stomatitis 
after treatment with the alkylating agents cyclophos-
phamide and ifosfamide [61]. It is possible that gender 
differences in the metabolism of both ifosfamide and 
cyclophosphamide might contribute to a potential in-
teraction between alkylating treatment, gender, disease 
outcome and acute toxicity. In fact, both ifosfamide and 
cyclophosphamide are inactive pro-drugs undergoing 
hydroxylation as a primary activating step mainly under 
control of CYP3A4 and CYP2B6, known to differently 
work in male and female. 
Female gender seems also to represent a risk fac-
tor to cognitive sequelae in children after treatment of 
central nervous system cancer. The rate of intelligence 
quotient decline during anticancer therapy is associated 
with several risk factors, including younger age at time 
of treatment, longer time since treatment, clinical vari-
ables such as hydrocephalus, use of radiotherapy and 
radiotherapy dose, and the volume of the brain that re-
ceived treatment. Anyway, some studies reported that, 
at equal risk factors, females showed a significantly 
higher vulnerability to intelligence quotient decline 
than men [63].
CONCLUSIONS
During the last decades, clinical trials and research in 
animal models have been gender unbalanced. On the 
basis of above reported data, it appears evident that sex 
influences pathophysiology, clinical signs, outcome and 
therapy of cancer. Thus, sex is an important stratifica-
tion factor that should be included in all cancer clini-
cal trials for a better understanding of biological differ-
ences between males and females, pivotal for improving 
targeted therapies. However, this new dimension of 
oncology needs additional investment in research, re-
form of medical teaching and, most of all, the political 
determination of changing the health approaches.
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